CN110833553A - Use of pyrazolopyrimidine derivatives for the treatment of Arthus response - Google Patents
Use of pyrazolopyrimidine derivatives for the treatment of Arthus response Download PDFInfo
- Publication number
- CN110833553A CN110833553A CN201810928269.4A CN201810928269A CN110833553A CN 110833553 A CN110833553 A CN 110833553A CN 201810928269 A CN201810928269 A CN 201810928269A CN 110833553 A CN110833553 A CN 110833553A
- Authority
- CN
- China
- Prior art keywords
- use according
- preparation
- arthus
- arthus reaction
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title claims abstract description 29
- 230000004044 response Effects 0.000 title claims description 8
- 208000000104 Arthus reaction Diseases 0.000 claims abstract description 24
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims abstract description 24
- 210000002966 serum Anatomy 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000000427 antigen Substances 0.000 claims abstract description 15
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- -1 vaccines Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010015150 Erythema Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- 238000000034 method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Abstract
The invention relates to the technical field of medicaments, in particular to application of pyrazolopyrimidine derivative in treatment of Arthus reaction. The Arthus reaction is associated with the binding of antigen and antibody to form an immune complex. The pyrazolopyrimidine derivative can obviously relieve the skin red and swollen symptom, reduce the expression level of immune complexes and IL-2 in serum, and generate a good treatment effect on Arthus reaction.
Description
Technical Field
The invention relates to the technical field of medicaments, in particular to application of pyrazolopyrimidine derivative in treatment of Arthus reaction.
Background
The Arthus reaction was discovered by Arthus in 1903 and is also known as the Arthur reaction. The mechanism of occurrence is: the xenogeneic serum of former several injections stimulates the organism to produce a large amount of antibodies, when injecting the same antigen again, because the antigen constantly is permeated in the blood vessel by subcutaneous, corresponding antibody in the blood flow is outwards dispersed by the vascular wall, and both meet in the vascular wall, form precipitative immune complex, deposit on venule vascular wall basement membrane, lead to necrotizing vasculitis even ulcer. When arthus phenomenon occurs locally, anaphylactic shock can be caused if alloantigens are injected intravenously. It is reported that the injection of penicillin, rabies vaccine, tetanus antitoxin and other drugs can cause Arthus reaction to different degrees, and is one of the clinically common type III hypersensitivity diseases. In addition, Arthus reactions are also frequent in Systemic Lupus Erythematosus (SLE) patients.
The pyrazolopyrimidine derivative (formula I) is a small molecule inhibitor targeted on FLT3 kinase, is a novel compound independently developed by the applicant, and the patent of the compound is granted in China, the United states, Japan and other areas at present.
Only the pyrazolopyrimidine derivatives are reported for the treatment of acute myeloid leukemia and psoriasis, and the use of the pyrazolopyrimidine derivatives for the treatment of Arthus response is not available.
Pyrazolopyrimidine derivative of formula I
Disclosure of Invention
To overcome the deficiencies of the prior art, the present invention provides the use of pyrazolopyrimidine derivatives in the treatment of Arthus reaction.
The purpose of the invention can be realized by the following technical scheme:
application of pyrazolopyrimidine derivative shown as formula I or pharmaceutically acceptable salt and hydrate thereof in preparation of drug for treating Arthus reaction
Preferably, the Arthus reaction is manifested by an elevated level of immune complexes in serum.
Preferably, the Arthus reaction is manifested by an elevated serum IL-2 level.
Preferably, the Arthus response is caused by lupus erythematosus.
Preferably, the Arthus reaction is associated with the binding of an antigen and an antibody to form an immune complex.
Preferably, the antigens include endogenous antigens and exogenous antigens.
Preferably, the exogenous antigens include: antibiotics, vaccines, insulin.
Preferably, the pharmaceutically acceptable salts include hydrochloride, sulfate, mesylate, phosphate.
The invention also provides application of a pharmaceutical composition in preparing a medicament for treating Arthus reaction, which is characterized in that the pharmaceutical composition comprises pyrazolopyrimidine derivative shown as the formula I or pharmaceutically acceptable salt or hydrate thereof as an active ingredient and pharmaceutically acceptable excipient.
Preferably, the pharmaceutical composition is an injection preparation, an oral preparation, an external preparation, a sustained release preparation, or a controlled release preparation.
Preferably, the oral preparation comprises tablets, granules and capsules.
Preferably, the pharmaceutical composition is a controlled release formulation, a sustained release formulation, an immediate release formulation.
The Arthus reaction is a type III allergy and is mainly characterized in that free antigen is combined with a corresponding antibody to form an Immune Complex (IC), and if the IC cannot be cleared in time, the IC can be deposited locally to cause a series of chain reactions to cause tissue damage. Clinical findings indicate that SLE patients have increased serum IL-2 levels, enhanced Th cell function, reduced Ts cell function, and enhanced B cell function, and maintain the production of large amounts of autoantibodies and immune complexes.
The pyrazolopyrimidine derivative is originally an FLT3 inhibitor, and researches show that the pyrazolopyrimidine derivative can obviously relieve the red and swollen symptoms of skin, reduce the expression level of immune complexes and IL-2 in serum, and has a good treatment effect on Arthus reaction.
Compared with the prior art, the method has the following advantages:
the pyrazolopyrimidine derivative provided by the invention is a novel drug for treating Arthus reaction, not only expands the drug selectivity of the existing Arthus reaction treatment and provides more drug choices for effective treatment of the Arthus reaction, but also further expands the application range of the pyrazolopyrimidine derivative as an FLT3 inhibitor.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1 Effect on Arthus response in rats
1. Experimental animals: SD rats, clean grade, sex and sex, body mass (200 + -20) g, purchased from Beijing Huafukang Biotech GmbH.
2. Experimental materials: pyrazolopyrimidine derivative was synthesized by the inventors. Mixing castor oil with ethanol 1: 1, passing through a sterile filter membrane of 0.22 mu m to obtain an ELE solution, weighing a certain mass of pyrazolopyrimidine derivative powder, dissolving the powder by using the ELE solution, adding a certain volume of sterilized water after the powder is completely dissolved, and uniformly mixing for later use. The volume ratio of the ELE solution to the sterile water is 1: 3.
3. establishing a model: according to Xutaiyun, published in 2002 as pharmacological experimental methodology, each rat is injected intramuscularly 0.5mL each week for 6 times, the former 3 times are ovalbumin-complete Freund's adjuvant, and the latter 3 times are ovalbumin-incomplete Freund's adjuvant.
4. Animal grouping and administration: on the last to the day of allergy, 70 SD rats were divided into 14 groups of 14 groups, each group consisting of a model group, a pyrazolopyrimidine derivative high dose group (hereinafter referred to as a high dose group), a pyrazolopyrimidine derivative medium dose group (hereinafter referred to as a medium dose group), a pyrazolopyrimidine derivative low dose group (hereinafter referred to as a low dose group), and a positive drug group, according to the physical mass. 10mL/kg of mixed solution of an ELE solution and distilled water in a volume ratio of 1:3 is administered to a model group by intragastric administration, 12mg/kg/d (1.2mg/mL of liquid medicine) of a pyrazolopyrimidine derivative is administered to a high-dose group by intragastric administration, 6mg/kg/d (0.6mg/mL of liquid medicine) of the pyrazolopyrimidine derivative is administered to a medium-dose group by intragastric administration, 3mg/kg/d (0.3mg/mL of liquid medicine) of the pyrazolopyrimidine derivative is administered to a low-dose group by intragastric administration, and 0.005g/kg/d of prednisone is administered to a positive-dose group. The preparation is administered by gavage 1 time daily (10mL/kg), and is administered continuously for 10 days. On day 10, the backs were injected intradermally with 1% ovalbumin, 0.2mL per spot.
5. Detecting the index
(1) The diameter of the local skin redness was observed at each spot 2, 4, 6, 8, 12, 24h after antigen challenge.
(2) After 24h of antigen attack, blood is taken from the eyeballs of the rats in each group, and the content of serum circulating immune complex is determined according to a polyethylene glycol method.
(3) The IL-2 level in the serum of rats was determined by Radioimmunoassay (RIA) according to the procedures described in the IL-2 detection kit.
6. The statistical method comprises the following steps: processing data by SPSS17.0, expressing measurement data by mean + -standard deviation, comparing measurement data among multiple groups by t test, and comparing count data by χ test2And (6) checking. P<A difference of 0.05 is statistically significant.
7. Results of the experiment
(1) Comparison of Back skin redness and swelling diameter at different times
TABLE 1 comparison of Back skin redness and swelling diameter at different times
P <0.05 compared to model group and △ P <0.05 compared to positive group.
As shown in table 1, after 2h antigen challenge, the dorsal skin of each group of rats showed hyperemia and hemorrhage, indicating that a rat Arthus response model had developed. Compared with the model group, the red and swollen diameters of the back skin of the high-dose group and the middle-dose group at the time point within the range of 2-12 h are obviously reduced (P is less than 0.05); the low dose group showed a significant reduction in the diameter of the red skin on the back (P <0.05) at 12h, with only a tendency to decrease at other time points. The above results also show that the degree of reduction of the skin redness diameter on the back of rats by the pyrazolopyrimidine derivative of the invention is positively correlated with the dose.
Compared with the positive medicine group, the time points of the high-dose group have no significant difference (P is more than 0.05) within the range of 2-12 h.
(2) Effect on serum immune complexes and IL-2
TABLE 2 Effect on serum immune complexes and IL-2
P <0.05 compared to model group and △ P <0.05 compared to positive group.
As shown in table 2, the high dose group, the medium dose group and the low dose group all significantly reduced the level of IL-2 in the serum of rats (P <0.05) compared to the model group; the high-dose group and the medium-dose group can obviously reduce the content of immune complexes in serum (P <0.05), and the low-dose group only shows a reduction trend. The results show that the reduction effect of the pyrazolopyrimidine derivative on serum immune complexes and IL-2 is positively correlated with the dosage.
Compared with the positive medicine group, the effects of the high and medium dose groups on the serum immune complex and the IL-2 content have no significant difference (P is more than 0.05).
Conclusion
The pyrazolopyrimidine derivative has a good treatment effect on Arthus reaction, can remarkably relieve the red and swollen symptoms of skin, and reduces the expression levels of immune complexes and IL-2 in serum.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (12)
1. Application of pyrazolopyrimidine derivative shown as formula I or pharmaceutically acceptable salt and hydrate thereof in preparation of drug for treating Arthus reaction
2. The use according to claim 1, wherein the Arthus reaction is manifested as an elevated level of immune complexes in serum.
3. The use according to claim 1, wherein the Arthus response is manifested by an increase in serum IL-2 levels.
4. The use according to claim 1, wherein the Arthus response is caused by lupus erythematosus.
5. The use according to claim 1, wherein the Arthus reaction is associated with the binding of an antigen and an antibody to form an immune complex.
6. The use of claim 5, wherein the antigens comprise endogenous and exogenous antigens.
7. The use of claim 6, wherein the exogenous antigen comprises: antibiotics, vaccines, insulin.
8. Use according to claim 1, wherein the pharmaceutically acceptable salts comprise hydrochloride, sulfate, mesylate, phosphate.
9. Use of a pharmaceutical composition comprising a pyrazolopyrimidine derivative of formula i, as defined in claim 1, or a pharmaceutically acceptable salt or hydrate thereof, as an active ingredient, and a pharmaceutically acceptable excipient for the preparation of a medicament for the treatment of Arthus reaction.
10. The use according to claim 9, wherein the pharmaceutical composition is an injection preparation, an oral preparation, an external preparation, a sustained-release preparation, or a controlled-release preparation.
11. The use according to claim 10, wherein the oral formulation comprises tablets, granules, capsules.
12. The use according to claim 9, wherein the pharmaceutical composition is a controlled release formulation, a sustained release formulation, an immediate release formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810928269.4A CN110833553A (en) | 2018-08-15 | 2018-08-15 | Use of pyrazolopyrimidine derivatives for the treatment of Arthus response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810928269.4A CN110833553A (en) | 2018-08-15 | 2018-08-15 | Use of pyrazolopyrimidine derivatives for the treatment of Arthus response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110833553A true CN110833553A (en) | 2020-02-25 |
Family
ID=69573097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810928269.4A Pending CN110833553A (en) | 2018-08-15 | 2018-08-15 | Use of pyrazolopyrimidine derivatives for the treatment of Arthus response |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110833553A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843066A (en) * | 2021-02-04 | 2021-05-28 | 广西中恒创新医药研究有限公司 | Composition containing pyrazolopyrimidine derivative with good solubility and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423314A (en) * | 2011-11-26 | 2012-04-25 | 济南环肽医药科技有限公司 | Medicine for treating immunological liver injury or immunological liver fibrosis |
| CN103833759A (en) * | 2012-11-23 | 2014-06-04 | 华东理工大学 | Pteridinone derivatives as BLK and FLT3 inhibitors and applications thereof |
| US20150274704A1 (en) * | 2014-03-28 | 2015-10-01 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| CN106543143A (en) * | 2015-09-22 | 2017-03-29 | 合肥中科普瑞昇生物医药科技有限公司 | New FLT3 kinase inhibitors of one class and application thereof |
| CN106568938A (en) * | 2016-10-11 | 2017-04-19 | 宁夏医科大学总医院 | Application of DKK1 in serum to diagnosis of systemic lupus erythenlatosus nephritis |
-
2018
- 2018-08-15 CN CN201810928269.4A patent/CN110833553A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423314A (en) * | 2011-11-26 | 2012-04-25 | 济南环肽医药科技有限公司 | Medicine for treating immunological liver injury or immunological liver fibrosis |
| CN103833759A (en) * | 2012-11-23 | 2014-06-04 | 华东理工大学 | Pteridinone derivatives as BLK and FLT3 inhibitors and applications thereof |
| US20150274704A1 (en) * | 2014-03-28 | 2015-10-01 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| CN106543143A (en) * | 2015-09-22 | 2017-03-29 | 合肥中科普瑞昇生物医药科技有限公司 | New FLT3 kinase inhibitors of one class and application thereof |
| CN106568938A (en) * | 2016-10-11 | 2017-04-19 | 宁夏医科大学总医院 | Application of DKK1 in serum to diagnosis of systemic lupus erythenlatosus nephritis |
Non-Patent Citations (3)
| Title |
|---|
| MA S，ET AL: "SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML", 《SCIENTIFIC REPORTS》 * |
| MIKHAIL OLFERIEV，ET AL: "Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus", 《CLINICAL IMMUNOLOGY》 * |
| 薛菁: "Wnt/β-catenin信号在狼疮肾炎病理发生中的作用及鉴别诊断价值研究", 《万方数据-学位论文》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112843066A (en) * | 2021-02-04 | 2021-05-28 | 广西中恒创新医药研究有限公司 | Composition containing pyrazolopyrimidine derivative with good solubility and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498959B2 (en) | Anti-CGRP antibody formulation | |
| CN110087632B (en) | Calcium Lactate Compositions and Methods of Use | |
| JP2023120445A (en) | Terlipressin compositions and methods of use thereof | |
| EA035686B1 (en) | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | |
| WO2015113200A1 (en) | Hydrochloric tapentadol injection and preparation method thereof | |
| RU2661618C1 (en) | Nephopam suppositories for the treatment of acute and chronic pain syndrome on a lipophilic basis and the method for their preparation | |
| CN110833553A (en) | Use of pyrazolopyrimidine derivatives for the treatment of Arthus response | |
| TW201338772A (en) | Pharmaceutical combinations | |
| WO2008034328A1 (en) | New use of ginsenoside compound-k in manufacturing medicaments | |
| KR101587140B1 (en) | Capsule containing mini-tablets comprising mosapride citrate for sustained-releasing formulation improving gastrointestinal disease and preparing the method thereof | |
| CN103330933B (en) | Pharmaceutical composition containing MFG or its salt | |
| CN102210686A (en) | Pharmaceutical composition containing ganciclovir compound, and preparation method thereof | |
| CN102274194B (en) | Pharmaceutical composition containing tropisetron compound and preparation method thereof | |
| CN111840297A (en) | Application of Idelalisib in preparing medicine for treating hepatic fibrosis diseases | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN104922677A (en) | Application of drug combination containing cepharanthine hydrochloride in preparing drug for treating leukopenia | |
| WO2023245470A1 (en) | Use of mdp analog in preparing medicament for treating inflammatory bowel disease | |
| CN102525896B (en) | Pharmaceutical composition of lappaconitine hydrobromide | |
| CN103330932B (en) | The pharmaceutical composition of a kind of MFG or its salt | |
| CN102274164A (en) | Sustained release gel for injection for paliperidone and paliperidone derivative | |
| CN105663028A (en) | Transrectal dosing double-layer sustained-release suppository containing dianhydrodulcitol | |
| CN105055324A (en) | Platinum anticancer oxaliplatin composition | |
| CN103933034B (en) | A kind of pharmaceutical composition and application containing luteolin | |
| CN116172976A (en) | Cyclobenzaprine hydrochloride sustained-release capsule and preparation method thereof | |
| CN110833554A (en) | Use of pyrazolopyrimidine derivatives for the treatment of autoimmune thyroid disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200225 |